Biocara Therapeutics Hits $30.99 High, Showcases Resilience in BiopharmaExplore BICARA THERAPEUTICS’ 2026 Nasdaq performance, $572M cap, and its innovative biopharma pipeline tackling unmet medical needs.BICARA THERAPEUTICS INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 09/11/2026, 22:36 2 minutes to read